Business Context and Reporting Period
The supplied filing is Aerpio Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2020, not Whitehawk Therapeutics, Inc. The company is a U.S. biopharmaceutical developer focused on Tie2-activating therapies, principally razuprotafib for glaucoma, COVID-19-related acute respiratory distress syndrome (ARDS), and diabetic complications. It has no approved or commercial products and has generated no product sales.
Financial Results and Liquidity
| Metric | Three months ended June 30, 2020 | Three months ended June 30, 2019 | Six months ended June 30, 2020 | Six months ended June 30, 2019 |
|---|---|---|---|---|
| License revenue | $15.0 million | $0 | $15.0 million | $0 |
| Research and development expense | $3.5 million | $2.3 million | $5.4 million | $7.9 million |
| General and administrative expense | $2.2 million | $2.8 million | $4.5 million | $6.1 million |
| Total operating expenses | $5.7 million | $6.0 million | $9.9 million | $14.8 million |
| Net income (loss) | $9.3 million | $(5.7) million | $5.4 million | $(14.2) million |
| Basic EPS | $0.23 | $(0.14) | $0.13 | $(0.35) |
- Quarterly operating margin was approximately 61.7%, and net margin was approximately 61.8%; six-month net margin was approximately 35.7%. These margins were driven by a nonrecurring $15.0 million license payment rather than product revenue.
- Cash and cash equivalents were $44.9 million at June 30, 2020, up from $38.5 million at December 31, 2019. Total assets were $45.7 million and stockholders’ equity was $42.6 million.
- Six-month operating cash flow was $6.4 million, compared with $(14.2) million in the prior-year period. The 2020 inflow primarily reflected the Gossamer payment.
- Total liabilities were $3.1 million, consisting primarily of accounts payable, accrued expenses, and operating lease liabilities. The filing does not disclose outstanding interest-bearing debt.
- Management stated that existing cash was expected to fund the current operating plan through at least the fourth quarter of 2021, but additional financing will be required to advance broader development activities and operate beyond the current plan.
Material Changes Versus the Prior Comparable Period
- License revenue and profitability increased sharply because Gossamer paid $15.0 million in May 2020 under an amendment to the GB004 license agreement. The amendment reduced future potential milestone payments and tiered royalty rates.
- Quarterly research and development expense increased 56.7% as the company planned its glaucoma Phase 2 program and the I-SPY COVID-19 ARDS program. Six-month research and development expense decreased 31.5% because certain 2019 clinical trials had been completed.
- General and administrative expense decreased 21.6% for the quarter and 26.0% for the six months, reflecting lower employee-related, legal, stock-based compensation, and office expenses.
- The $0.9 million restructuring expense recorded in the 2019 periods did not recur in 2020. Approximately $0.3 million of restructuring liability remained at June 30, 2020 and was expected to be substantially paid by October 31, 2020.
- Outstanding warrants decreased to 600,000 shares from 917,562 at year-end because 317,562 warrants expired in March 2020. Common shares outstanding remained 40,588,004 at June 30, 2020.
Guidance, Outlook, Risks, and Unusual Items
- The company initiated a Phase 2 glaucoma trial in June 2020 targeting approximately 195 patients and expected results in the fourth quarter of 2020, subject to enrollment and COVID-19-related delays.
- The company expected the I-SPY COVID-19 trial of razuprotafib for critical COVID-19 ARDS to begin in the third quarter of 2020, with updates anticipated in the first half of 2021.
- After the reporting period, the company announced funding for another COVID-19 ARDS trial. MTEC was expected to provide up to $5.1 million, while the company expected to contribute $2.8 million of in-kind spending; completion was expected in the first quarter of 2021.
- Gossamer reported Phase 1b GB004 results in the second quarter and planned to begin a Phase 2 inflammatory bowel disease program in the first half of 2021. Future milestones and royalties remained fully constrained and were not included in transaction price.
- COVID-19 could delay clinical enrollment, site operations, manufacturing, monitoring, supply chains, and regulatory interactions. The ultimate impact was described as highly uncertain.
- The company continues to incur operating losses excluding license payments, has an accumulated deficit of $136.9 million, and expects significant future spending. Failure to obtain additional capital could require delaying, reducing, or terminating development programs.
- Management continued to explore strategic alternatives, including a potential acquisition, merger, asset sale, licensing transaction, or business combination, but provided no assurance that a transaction would occur.
- On August 5, 2020, after the reporting date, the company sold 1.48 million shares under its at-the-market facility for net proceeds of $2.3 million.
- Management reported effective disclosure controls and no material changes to internal control over financial reporting. No material legal proceedings were disclosed.
Most Important Facts to Verify
- Confirm the issuer identity: the supplied filing is for Aerpio Pharmaceuticals, Inc., whereas the request identifies Whitehawk Therapeutics, Inc.
- Determine how much of the reported profit and positive operating cash flow reflects the one-time $15.0 million Gossamer payment and whether comparable future payments are expected.
- Verify enrollment, timing, and results of the glaucoma Phase 2 trial and the COVID-19 ARDS programs, including the effect of pandemic-related delays.
- Assess the company’s cash runway against actual clinical spending and the need for additional, potentially dilutive financing.
- Review the amended Gossamer agreement for the reduction in future milestones and royalty economics, as well as termination provisions.
- Verify the post-period $2.3 million equity financing and the resulting share count and dilution.
- Monitor Nasdaq listing compliance, clinical and regulatory risks, third-party manufacturing dependence, intellectual-property protection, and the company’s ongoing strategic-alternatives process.